{"id":"https://openalex.org/W2591005579","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.tps119","title":"A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.","display_name":"A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2591005579","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.tps119","mag":"2591005579"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.tps119","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.tps119","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.tps119","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112141176","display_name":"M. J. Higgins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. J. Higgins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087372519","display_name":"N. Gabrail","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Y. Gabrail","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068666503","display_name":"Kathy D. Miller","orcid":"https://orcid.org/0000-0002-7125-883X","observed_orcids":["https://orcid.org/0000-0002-7125-883X","https://orcid.org/0000-0001-8537-0710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Miller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108263966","display_name":"S. Agresta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. V. Agresta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"S. Sharma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Sharma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058357910","display_name":"Charlotte Fenton McDonagh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. McDonagh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111019291","display_name":"J. Murray","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Murray","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109730100","display_name":"K. Andreas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Andreas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025130230","display_name":"Sasha Frye","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Frye","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018176516","display_name":"V. M. Moyo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. M. Moyo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108270642","display_name":"Clet Niyikiza","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Niyikiza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5013104624","display_name":"Paula D. Ryan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. D. Ryan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"TPS119","last_page":"TPS119"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mm-111","display_name":"MM.111","score":1.0},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9509999752044678},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9240000247955322},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9649999737739563},{"id":"https://openalex.org/keywords/neuregulin-1","display_name":"neuregulin-1","score":0.8309999704360962},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.6330000162124634},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7459999918937683},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7799999713897705},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7960000038146973},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8830000162124634},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7099999785423279}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8823922872543335},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7947705388069153},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.719141960144043},{"id":"https://openalex.org/C115456853","wikidata":"https://www.wikidata.org/wiki/Q17917132","display_name":"ERBB3","level":4,"score":0.5349748134613037},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5288851261138916},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4904119670391083},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.489082396030426},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45204830169677734},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4427981376647949},{"id":"https://openalex.org/C2779251935","wikidata":"https://www.wikidata.org/wiki/Q5385089","display_name":"ErbB","level":3,"score":0.4202336072921753},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40061014890670776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3700815439224243},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.2564852237701416},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.10573101043701172}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.tps119","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.tps119","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.tps119","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2248107633","https://openalex.org/W2315705238","https://openalex.org/W2776588450","https://openalex.org/W2021588213","https://openalex.org/W2316509354","https://openalex.org/W2082165279","https://openalex.org/W2151464858","https://openalex.org/W3000354799","https://openalex.org/W2317147303","https://openalex.org/W2283626918"],"abstract_inverted_index":{"TPS119":[0],"Background:":[1],"The":[2,186],"ErbB2/ErbB3":[3,46],"oncogenic":[4],"heterodimer":[5,47],"is":[6,35,75,153,176,209,229,293],"the":[7,45,120,131,165,205,217,223,240],"most":[8],"potent":[9],"ErbB":[10],"receptor":[11,19],"pairing":[12],"with":[13,139,213],"respect":[14],"to":[15,105,237,290],"strength":[16],"of":[17,51,58,80,103,123,135,171,199,244,253,259,263,268,283],"interaction,":[18],"tyrosine":[20],"phosphorylation,":[21,66],"and":[22,30,48,70,86,93,113,133,141,169,220,242,255,257,265],"downstream":[23],"signaling":[24,96],"through":[25],"mitogen":[26],"activated":[27],"protein":[28,41],"kinase":[29,32],"phosphoinositide-3":[31],"pathways.":[33],"MM-111":[34,62,118,136,172,200],"a":[36,76,154,177,191],"novel":[37],"bispecific":[38],"antibody":[39],"fusion":[40],"that":[42,117,162],"specifically":[43,91],"targets":[44],"abrogates":[49],"binding":[50],"ErbB3\u2019s":[52],"ligand":[53],"heregulin.":[54,266],"In":[55],"preclinical":[56,114],"models":[57],"HER-2+":[59,146],"solid":[60],"tumors,":[61],"inhibits":[63],"ligand-induced":[64],"ErbB3":[65,95],"cell":[67],"cycle":[68],"progression,":[69],"tumor":[71],"growth.":[72],"ErbB2":[73,106],"(HER2)":[74],"well":[77],"established":[78],"target":[79],"anticancer":[81],"agents":[82,109],"such":[83],"as":[84,99],"trastuzumab":[85,140,214],"lapatinib":[87],"for":[88],"HER2+":[89],"cancers,":[90],"breast":[92,148],"gastric.":[94],"has":[97],"emerged":[98],"an":[100,183,231,251],"important":[101],"mechanism":[102],"resistance":[104],"(HER-2)":[107],"targeted":[108],"in":[110,137,145,211],"clinical":[111],"use,":[112],"data":[115],"demonstrates":[116],"potentiates":[119],"antitumor":[121],"activity":[122],"trastuzumab.":[124,174],"This":[125,152],"first-in-human":[126],"phase":[127,155,180,189,206,226],"I/II":[128],"study":[129,161],"evaluates":[130],"safety":[132,241,254],"tolerability":[134],"combination":[138,212],"preliminarily":[142],"explores":[143],"efficacy":[144,170,243,256],"advanced":[147],"cancer":[149],"(ABC).":[150],"Methods:":[151],"I/II,":[156],"open":[157],"label,":[158],"multicenter,":[159],"dose-escalation":[160],"will":[163,201,234,249],"evaluate":[164,239],"safety,":[166],"pharmacokinetics":[167],"(PK),":[168],"+":[173,194],"There":[175],"dose":[178,187,208,219,228],"escalation":[179,188],"followed":[181],"by":[182],"expansion":[184,232],"cohort.":[185],"utilizes":[190],"standard":[192],"\u201c3":[193],"3\u201d":[195],"design":[196],"where":[197],"doses":[198],"be":[202,235],"escalated":[203],"until":[204],"II":[207,227],"identified":[210],"given":[215],"at":[216],"approved":[218],"regimen.":[221],"Once":[222],"MTD":[224],"or":[225],"identified,":[230],"cohort":[233,291],"enrolled":[236],"further":[238],"doublet.":[245],"Key":[246],"exploratory":[247],"analyses":[248],"include":[250],"evaluation":[252],"levels":[258],"expression":[260],"and/or":[261],"amplification":[262],"HER2":[264],"As":[267],"January":[269],"1":[270,273],"2011,":[271],"cohorts":[272],"thru":[274],"2":[275],"have":[276,286],"been":[277,287],"completed":[278],"without":[279],"DLT.":[280],"A":[281],"total":[282],"7":[284],"patients":[285],"treated.":[288],"Enrollment":[289],"3":[292],"ongoing.":[294]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-03-03T00:00:00"}